Glenmark Pharma Q3 Earnings

Jump to

Glenmark rises 2.7% as Citi maintains buy post Q3 earnings

Glenmark Pharma jumped as much as 2.7 percent in early trade on Thursday as the research firm Citi maintained a buy rating on the stock with a target price of Rs 660.
Glenmark slips despite strong Q3 nos, CS outperform report

Healthcare firm Glenmark Pharma fell more than 2 percent on profit booking after rising as much as 5 percent in early trade on Wednesday due to strong numbers in the third quarter.
Glenmark Pharma Q3 profit seen up 4 times to Rs 181 cr

Glenmark Pharma is set to declare its results for the third quarter of financial year 2012-13 on Tuesday. Analysts on an average expect profit after tax to grow 4 times year-on-year to Rs 181 crore in the quarter due to EBITDA expansion and one off income.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Glenmark Pharma Q3 Earnings

Glenmark rises 2.7% as Citi maintains buy post Q3 earnings

Glenmark slips despite strong Q3 nos, CS outperform report

Glenmark Pharma Q3 profit seen up 4 times to Rs 181 cr